InvestSMART

Atomo Diagnostics Limited (ASX:AT1)

ALERT: Price-sensitive ASX Announcement for AT1
Current share price for AT1 : $0.017 -0.02 (-54.05%)+
Announcement
Release
15 Jan 2026 8:53AM
Price at Release
$0.037
Full Release
download
Summary
On 15 January 2026, Atomo Diagnostics Limited, listed as ASX:AT1, announced securing a significant order worth $502,000 for their HIV Self-Tests to be supplied to an African country. These tests are manufactured under the Mylan brand and funded by the Global Fund. The order is considered materially significant, with the tests expected to be supplied in March. This reflects ongoing demand for their HIV Self-Test in Africa, essential for providing accessible diagnostic tools.
Key Points
  • Atomo Diagnostics secured a $502,000 order for HIV Self-Tests.
  • Supply is targeted for an African country under the Mylan brand.
  • The order is funded by the Global Fund.
  • Delivery of the HIV Self-Tests is scheduled for March.
  • Revenue from this order is considered material for Atomo.
  • The announcement was authorized by the Managing Director & CEO.
  • Atomo is an Australian company specializing in rapid diagnostic tests.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.